Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mitophagy protects β cells from inflammatory damage in diabetes
Vaibhav Sidarala, … , Leslie S. Satin, Scott A. Soleimanpour
Vaibhav Sidarala, … , Leslie S. Satin, Scott A. Soleimanpour
Published November 24, 2020
Citation Information: JCI Insight. 2020;5(24):e141138. https://doi.org/10.1172/jci.insight.141138.
View: Text | PDF
Research Article Endocrinology

Mitophagy protects β cells from inflammatory damage in diabetes

  • Text
  • PDF
Abstract

Inflammatory damage contributes to β cell failure in type 1 and 2 diabetes (T1D and T2D, respectively). Mitochondria are damaged by inflammatory signaling in β cells, resulting in impaired bioenergetics and initiation of proapoptotic machinery. Hence, the identification of protective responses to inflammation could lead to new therapeutic targets. Here, we report that mitophagy serves as a protective response to inflammatory stress in both human and rodent β cells. Utilizing in vivo mitophagy reporters, we observed that diabetogenic proinflammatory cytokines induced mitophagy in response to nitrosative/oxidative mitochondrial damage. Mitophagy-deficient β cells were sensitized to inflammatory stress, leading to the accumulation of fragmented dysfunctional mitochondria, increased β cell death, and hyperglycemia. Overexpression of CLEC16A, a T1D gene and mitophagy regulator whose expression in islets is protective against T1D, ameliorated cytokine-induced human β cell apoptosis. Thus, mitophagy promotes β cell survival and prevents diabetes by countering inflammatory injury. Targeting this pathway has the potential to prevent β cell failure in diabetes and may be beneficial in other inflammatory conditions.

Authors

Vaibhav Sidarala, Gemma L. Pearson, Vishal S. Parekh, Benjamin Thompson, Lisa Christen, Morgan A. Gingerich, Jie Zhu, Tracy Stromer, Jianhua Ren, Emma C. Reck, Biaoxin Chai, John A. Corbett, Thomas Mandrup-Poulsen, Leslie S. Satin, Scott A. Soleimanpour

×

Figure 4

Nitric oxide/reactive oxygen species induce mitophagy in β cells.

Options: View larger image (or click on image) Download as PowerPoint
Nitric oxide/reactive oxygen species induce mitophagy in β cells.
(A) (L...
(A) (Left) Assessment of mitophagy by flow cytometric quantification of acid/neutral ratio from FVB/N mt-Keima islets following treatment with valinomycin (250 nM for 3 hours), rotenone (250 nM for 3 hours), and DPTA/NO (600 μM for 1 hour). n = 3/group. *P < 0.05 by ANOVA. (Right) Flow cytometric quantification of eGFP and mCherry fluorescence of Min6 β cells transfected with mitochondria-targeted tandem mCherry-eGFP mitophagy reporter following treatment with valinomycin (250 nM for 4 hours), rotenone (500 nM for 4 hours), paraquat (1 mM for 4 hours), and DPTA/NO (600 μM for 6 hours). n = 3/group; *P < 0.05 by ANOVA. (B) Mfn1 and Mfn2 expression by WB (with densitometry normalized to cyclophilin B) in Min6 β cells treated with 5 μM FCCP for 6 hours or 500 nM rotenone for indicated time course. n = 3/group; P < 0.05 by ANOVA. (C) Mfn2 and Parkin (Prkn) expression by WB (with densitometry normalized to cyclophilin B) in mouse islets treated with DPTA/NO (600 μM) for indicated time course. n=4/group; P < 0.05 by ANOVA. (D) Mfn1 and Mfn2 expression by WB (with densitometry normalized to cyclophilin B) in Min6 β cells treated DPTA/NO (600 μM) for indicated time course. n = 3/group; P < 0.05 by ANOVA.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts